Patent ID: 9668995
Date: 2017-06-06
CPC Classifications: A61K,A61P

Claim:
1. A method of extending the duration of on-time in a human patient undergoing dopamine replacement therapy for Parkinson's Disease, said method comprising at least once daily oral administration of a therapeutically effective dose of at least 0.01 μg/kg body weight of a selective 5-hydroxytryptamine 1a receptor agonist to the human patient having Parkinson's Disease and undergoing dopamine replacement therapy for the treatment of Parkinson's Disease, wherein the patient exhibits wearing-off of anti-parkinsonian efficacy of the dopamine replacement therapy or has developed “on-off” syndrome, and wherein the at least once daily oral administration of a therapeutically effective dose of at least 0.01 μg/kg body weight of a selective 5-hydroxytryptamine 1a receptor agonist increases the duration of on-time in the human patient.